The European Commission signed its fourth contract to purchase 300 million doses of a future potential COVID-19 vaccine with the BioNTech-Pfizer alliance. This follows the companies’ recent announcement that their vaccine candidate has so far shown to have a 90% efficacy rate. However, exploratory talks for a deal had already been completed in September 2020.
The deal includes 200 million doses of BioNTech-Pfizer’s vaccine candidate, the option to purchase 100 million more, and the potential to donate doses to lower- and middle-income countries or to redirect to other European countries. This is BioNTech-Pfizer’s largest initial order of vaccine doses so far.
The vaccine candidate is currently undergoing Phase III clinical trials. It will be manufactured in both Pfizer’s Belgian and BioNTech’s German production facilities.
The European Commission has also signed similar vaccine deals with AstraZeneca, Sanofi-GSK, and Janssen Pharmaceutica NV (Johnson & Johnson).
Press release - European Commission
Press release - Pfizer